安科生物：姚建平计划减持公司股份100万股

Group 1 - The core point of the article is that Anke Bio (SZ 300009) announced that senior management personnel Yao Jianping plans to reduce his shareholding by 1 million shares, which accounts for 0.06% of the total share capital, within three months starting from September 26, 2025 [1] - As of the first half of 2025, Anke Bio's revenue composition is as follows: 73.51% from genetic engineering drugs, 16.77% from other businesses, and 9.72% from external patches [1] - Anke Bio's market capitalization is currently valued at 18.5 billion yuan [1]